{"id":"haloperidol-injection","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Extrapyramidal symptoms (dystonia, akathisia, parkinsonism)"},{"rate":"10-20%","effect":"Sedation"},{"rate":"5-15%","effect":"Orthostatic hypotension"},{"rate":"3-5% per year","effect":"Tardive dyskinesia (chronic use)"},{"rate":"<1%","effect":"Neuroleptic malignant syndrome"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL1200986","moleculeType":"Small molecule","molecularWeight":"530.12"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Haloperidol is a first-generation (typical) antipsychotic that antagonizes dopamine D2 receptors, particularly in the mesolimbic and mesocortical pathways. This dopamine blockade reduces positive symptoms of psychosis such as hallucinations and delusions, and also provides sedative and antiemetic effects. The injection formulation allows for rapid onset and is used in acute psychiatric emergencies.","oneSentence":"Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:44.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation and psychosis"},{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania)"},{"name":"Severe behavioral disturbances"},{"name":"Delirium"}]},"trialDetails":[{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT06395428","phase":"PHASE4","title":"Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department","status":"RECRUITING","sponsor":"Western Michigan University School of Medicine","startDate":"2024-07-09","conditions":"Back Pain, Chronic Pain","enrollment":75},{"nctId":"NCT06168773","phase":"PHASE2, PHASE3","title":"Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Delirium in Old Age","enrollment":135},{"nctId":"NCT05995457","phase":"NA","title":"The IM-ZBULLE Study : \" Z-track \" and \" Airlock \" Techniques During Intramuscular Injection of Haloperidol Decanoate","status":"UNKNOWN","sponsor":"Centre Hospitalier St Anne","startDate":"2023-09-01","conditions":"Schizophrenia; Psychosis","enrollment":84},{"nctId":"NCT05803642","phase":"PHASE3","title":"A Study of Olanzapine in Patients With Acute Agitation","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-03-28","conditions":"Acute Agitation","enrollment":318},{"nctId":"NCT03392376","phase":"PHASE4","title":"Agents Intervening Against Delirium in Intensive Care Unit","status":"UNKNOWN","sponsor":"Zealand University Hospital","startDate":"2018-06-13","conditions":"Delirium","enrollment":1000},{"nctId":"NCT02380118","phase":"PHASE4","title":"IM Olanzapine Versus Haloperidol or Midazolam","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Acute Agitation, Behavioural Emergency","enrollment":167},{"nctId":"NCT05246631","phase":"PHASE4","title":"Haloperidol and Dexamethasone Towards Postoperative Nausea and Pain in Adult After Laparoscopy","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2020-01-01","conditions":"Laparoscopy, Postoperative Nausea and Vomiting","enrollment":80},{"nctId":"NCT04327843","phase":"PHASE3","title":"Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2019-11-05","conditions":"Schizophrenia, Medication Nonadherence, Schizo Affective Disorder","enrollment":22},{"nctId":"NCT00723606","phase":"PHASE3","title":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":376},{"nctId":"NCT03375671","phase":"PHASE2","title":"Rapid Agitation Control With Ketamine in the Emergency Department","status":"COMPLETED","sponsor":"David Barbic","startDate":"2018-05-29","conditions":"Violent Aggressive Behavior, Ketamine","enrollment":81},{"nctId":"NCT01639599","phase":"NA","title":"Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2012-03","conditions":"Gynecological Disease","enrollment":150},{"nctId":"NCT02085447","phase":"NA","title":"A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-05","conditions":"Psychotic Disorders, Schizophrenia, Schizoaffective Disorder","enrollment":30},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT03211897","phase":"","title":"Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-06-15","conditions":"Agitation,Psychomotor","enrollment":737},{"nctId":"NCT02909465","phase":"PHASE4","title":"Reducing Ketamine-Induced Agitation, by Midazolam or Haloperidol Premedication After Adult Procedural Sedation","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2016-07","conditions":"Ketamine Induced Agitation","enrollment":185},{"nctId":"NCT01136772","phase":"PHASE4","title":"A Comparison of Long-acting Injectable Medications for Schizophrenia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":311},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT02493192","phase":"PHASE4","title":"Birth Ball Versus Meperidine and Haloperidol Injection for Pain Relief During First Stage of Labour","status":"UNKNOWN","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2015-07","conditions":"Parturition, Humanizing Deliver, Labor Pain","enrollment":110},{"nctId":"NCT01157351","phase":"PHASE4","title":"15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-05","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT01152697","phase":"NA","title":"Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2010-06","conditions":"Patient Noncompliance","enrollment":30},{"nctId":"NCT01939093","phase":"PHASE4","title":"Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2010-03","conditions":"Methamphetamine-induced Psychosis","enrollment":80},{"nctId":"NCT01193621","phase":"PHASE1","title":"Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT01193166","phase":"PHASE4","title":"Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital","status":"WITHDRAWN","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01750541","phase":"PHASE3","title":"Haloperidol vs. Valproate in Agitation","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2012-12","conditions":"Psychomotor Agitation","enrollment":56},{"nctId":"NCT01485692","phase":"NA","title":"Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Psychomotor Agitation","enrollment":120},{"nctId":"NCT00859872","phase":"PHASE4","title":"Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2008-08","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT00838032","phase":"PHASE4","title":"Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2008-08","conditions":"Acute Schizophrenia","enrollment":70}],"_emaApprovals":[],"_faersSignals":[{"count":19,"reaction":"NEUROLEPTIC MALIGNANT SYNDROME"},{"count":9,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":9,"reaction":"PULMONARY EMBOLISM"},{"count":8,"reaction":"PRODUCT USE ISSUE"},{"count":7,"reaction":"CARDIAC ARREST"},{"count":6,"reaction":"CATATONIA"},{"count":6,"reaction":"TORSADE DE POINTES"},{"count":5,"reaction":"CONDITION AGGRAVATED"},{"count":5,"reaction":"DRUG INTERACTION"},{"count":5,"reaction":"SEIZURE"}],"_approvalHistory":[],"publicationCount":101,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Magnesium Sulphate","Serenase","haloperidol"],"phase":"marketed","status":"active","brandName":"Haloperidol Injection","genericName":"Haloperidol Injection","companyName":"Hennepin Healthcare Research Institute","companyId":"hennepin-healthcare-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation. Used for Acute agitation and psychosis, Schizophrenia, Bipolar disorder (acute mania).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}